Licensing opportunities
Nutraceuticals:
Type of technology: screening platform
Indication: testing active (therapeutic) compounds for adverse effects of Reactive Oxygen species
- Genomics-based high-throughput screening method that is superior to other existing complex battery of methods for discovering ROS type-specific antioxidants
- Simple, Fast, High-Throughput
Oncology and growth:
Type of technology: diagnostics & screening platform
Indication: the diagnosis of dilated cardiomyopathy, muscular dystrophy and partial lipodystrophy
Phase: Preclinical
- Early detection of nuclear envelopathies and the prediction of the severity of this disease.
- Allows for distinguishing between different types of laminopathies.
Cardiovascular:
Type of technology: platform --> optimized leads
Indication: (I) treatment of diseases characterized by excessive fibrosis, e.g. cardiac hypertrophy, liver fibrosis, lung fibrosis and hypertrophic scarring of the skin after burning injuries; (II) diagnostic use for molecular imaging.
Phase: Preclinical --> optimized leads
- First low molecular weight (LMW) agonist
- Specific for frizzled-1 (Fzd-1) and -2 (Fzd-2)
- High bio-stability and near optimal receptor affinity
Type of technology: platform --> optimized leads
Indication: (I) prevention and/or treatment of fibrosis resulting in malfunctioning of vital organs such as the heart (e.g. healing after myocardial infarct), lungs, kidney and liver, treatment of injured skeletal muscles, the attenuation of the aging process and cancer. (II) diagnostic use for molecular imaging of for instance the healing process after incidences such as myocardial infarction.
Phase: Preclinical --> optimized leads
- First low molecular weight (LMW) antagonist
- Specific for frizzled-1 (Fzd-1) and -2 (Fzd-2)
- High bio-stability and near optimal receptor affinity
